DENTSPLY SIRONA Inc. (NASDAQ:XRAY)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Tuesday. They presently have a $68.00 price objective on the medical instruments supplier’s stock. HC Wainwright’s price target would indicate a potential upside of 18.86% from the company’s current price.

Other research analysts have also recently issued reports about the company. Jefferies Group LLC lowered their price objective on DENTSPLY SIRONA from $72.00 to $66.00 and set a “buy” rating for the company in a research report on Wednesday, August 23rd. Zacks Investment Research raised DENTSPLY SIRONA from a “hold” rating to a “buy” rating and set a $72.00 price objective for the company in a research report on Thursday, July 13th. BidaskClub raised DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research report on Friday, June 30th. Stifel Nicolaus reaffirmed a “buy” rating and set a $66.00 price objective (down from $70.00) on shares of DENTSPLY SIRONA in a research report on Thursday, August 10th. Finally, TheStreet cut DENTSPLY SIRONA from a “b” rating to a “c+” rating in a research report on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $65.67.

Shares of DENTSPLY SIRONA (XRAY) opened at 57.21 on Tuesday. DENTSPLY SIRONA has a 1-year low of $52.54 and a 1-year high of $65.68. The firm has a 50-day moving average price of $56.90 and a 200-day moving average price of $61.30. The stock’s market capitalization is $13.13 billion.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.65. The business had revenue of $992.70 million during the quarter, compared to analysts’ expectations of $1 billion. DENTSPLY SIRONA had a positive return on equity of 7.24% and a negative net margin of 20.57%. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.76 EPS. On average, equities research analysts forecast that DENTSPLY SIRONA will post $2.68 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/10/05/dentsply-sirona-inc-xray-rating-reiterated-by-hc-wainwright.html.

Several institutional investors have recently bought and sold shares of the company. Lord Abbett & CO. LLC lifted its holdings in shares of DENTSPLY SIRONA by 17.6% in the 2nd quarter. Lord Abbett & CO. LLC now owns 696,865 shares of the medical instruments supplier’s stock valued at $45,185,000 after purchasing an additional 104,153 shares during the last quarter. Toronto Dominion Bank lifted its holdings in shares of DENTSPLY SIRONA by 23.8% in the 2nd quarter. Toronto Dominion Bank now owns 81,534 shares of the medical instruments supplier’s stock valued at $5,286,000 after purchasing an additional 15,680 shares during the last quarter. Koch Industries Inc. purchased a new stake in shares of DENTSPLY SIRONA in the 2nd quarter valued at about $358,000. Westwood Holdings Group Inc. purchased a new stake in shares of DENTSPLY SIRONA in the 2nd quarter valued at about $17,815,000. Finally, Security National Bank of SO Dak lifted its holdings in shares of DENTSPLY SIRONA by 1.1% in the 2nd quarter. Security National Bank of SO Dak now owns 18,805 shares of the medical instruments supplier’s stock valued at $1,219,000 after purchasing an additional 207 shares during the last quarter. 93.87% of the stock is owned by institutional investors and hedge funds.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Stock Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related stocks with our FREE daily email newsletter.